Critical Contrast: Lotus Pharmaceuticals (OTCMKTS:LTUS) versus Evotec (NASDAQ:EVO)

Lotus Pharmaceuticals (OTCMKTS:LTUS) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.

Institutional and Insider Ownership

5.8% of Evotec shares are owned by institutional investors. 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Lotus Pharmaceuticals has a beta of -1.68, meaning that its share price is 268% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Lotus Pharmaceuticals and Evotec, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lotus Pharmaceuticals	0	0	0	0	0.00
Evotec	1	0	3	0	2.50

Evotec has a consensus target price of $7.00, suggesting a potential upside of 135.69%. Given Evotec’s stronger consensus rating and higher probable upside, analysts clearly believe Evotec is more favorable than Lotus Pharmaceuticals.

Earnings & Valuation

This table compares Lotus Pharmaceuticals and Evotec”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lotus Pharmaceuticals	N/A	N/A	-$30,000.00	N/A	N/A
Evotec	$891.97 million	1.18	-$117.12 million	N/A	N/A

Lotus Pharmaceuticals has higher earnings, but lower revenue than Evotec.

Profitability

This table compares Lotus Pharmaceuticals and Evotec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lotus Pharmaceuticals	N/A	N/A	N/A
Evotec	-26.20%	-24.93%	-11.35%

Summary

Evotec beats Lotus Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Lotus Pharmaceuticals

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.